Mazdutide, cotadutide and oxyntomodulin all exhibit activity at glucagon-like peptide-1 (GLP-1) and glucagon receptors. However, their molecular structures, origins and pharmacological characteristics differ.
For UK laboratories comparing GLP-1 and glucagon dual-agonist research peptides, these distinctions matter more than broad supplier descriptions such as “dual-action metabolic peptide”.
How Do GLP-1 and Glucagon Dual Agonists Work?
GLP-1 receptor activation is associated with glucose-dependent insulin secretion and appetite-related signalling.
Glucagon receptor activation influences hepatic glucose metabolism and energy regulation.
Dual agonists are studied to understand how simultaneous activation of these pathways affects metabolic responses.
However, receptor potency, signalling characteristics and experimental outcomes vary between compounds.
Mazdutide vs Cotadutide vs Oxyntomodulin
| Research peptide | Molecular origin | Key research distinction |
|---|---|---|
| Mazdutide (IBI362) | Synthetic modified peptide | Designed for prolonged dual-receptor activity |
| Cotadutide (MEDI0382) | Synthetic modified peptide | Studied for combined metabolic and liver-related effects |
| Oxyntomodulin | Endogenous proglucagon-derived peptide | Native 37-amino-acid structure with dual-receptor activity |
Oxyntomodulin contains the glucagon sequence with an eight-amino-acid C-terminal extension.
Mazdutide and cotadutide are distinct synthetic compounds. Their structural modifications and pharmacological profiles should be assessed individually.
Five Factors UK Buyers Should Compare
1. Exact Molecular Identity
Confirm the peptide sequence, molecular mass, structural modifications and declared chemical form.
A supplier listing should distinguish native oxyntomodulin from modified analogues.
2. Receptor Activity Evidence
Where experiments require quantitative receptor responses, request relevant assay information.
A purity certificate cannot establish receptor potency.
3. Peptide Content
Compare actual peptide content rather than relying solely on gross vial weight or advertised concentration.
4. Product Format and Stability
For lyophilised powders, check excipients and supported storage conditions.
For prepared solutions, verify concentration, solvent composition and available stability data.
5. Batch-Specific Analytical Records
Review the COA, mass spectrometry evidence and chromatographic results.
Confirm that the batch identifier corresponds to the material being offered.
For compound-specific procurement information, see our mazdutide supplier checklist and cotadutide COA comparison.
Frequently Asked Questions
1. Are all dual agonists structurally identical?
No. Their sequences and modifications differ.
2. Is oxyntomodulin naturally occurring?
Yes. It is derived from proglucagon.
3. Is mazdutide the same as cotadutide?
No. They are distinct synthetic peptides.
4. Does HPLC purity establish receptor potency?
No. Functional assays are needed.
5. Can supplier COAs be compared directly?
Only after assessing methods, specifications and batch correspondence.
6. Should all three peptides have identical storage requirements?
No. Stability depends on the individual material and formulation.
Conclusion
Comparing GLP-1 and glucagon dual-agonist research peptides requires attention to molecular identity, receptor pharmacology and batch-specific evidence. UK laboratories should select materials according to experimental requirements rather than assumed compound equivalence.
For laboratory research only. Not intended for human administration or clinical use.
Scientific and Technical References
- PubMed — GLP-1/glucagon dual agonist research: https://pubmed.ncbi.nlm.nih.gov/?term=GLP-1+glucagon+dual+agonists
- ClinicalTrials.gov — Mazdutide research records: https://clinicaltrials.gov/search?term=mazdutide
- ClinicalTrials.gov — Cotadutide research records: https://clinicaltrials.gov/search?term=cotadutide
These references provide scientific context and do not independently verify any supplier’s research materials.
One comment